AstraWell Venture Studio

Venture Studio

Leadership in Womens Health

Maroon Venture Fund and Wellbeing of Women (the largest Women Health institution in the UK) are excited to announce AstraWell - a multi-year, multi-initiative "game-changing" partnership to advance Womens Health in the United States and United Kingdom tackling some of the most critical issues in Womens Health today.

Please see full Press Release here. Under Partnership several initiatives will be launched to accelerate: 

  • Critical R&D innovation, venture development, product solutions in Women’s Health led by clinical excellence
  • Catalytic capital to fund Womens Health innovation
  • Strengthen innovation consortiums, commercial venture platforms, and robust scaling in Womens Health in the US, UK, US-UK, and eventually globally
Venture studio - first initiative
Venture studio - first initiative
Most effective health advances do not occur in silos but fostered through collaboration across geographies and by best-in-class partnerships reflecting quality data, access, deep expertise, and execution capability.

AstraWell Venture Studio is the 1st initiative launched under Partnership to advance venture development and commercial scaling addressing chronic Health and Climate conditions disproportionately impacting Women's Health.

This hybrid platform also offers optional on-site engagement and sessions in Houston, Boston, New York, Oban, and London.

Venture Studio Differentiation & Delivery

AstraWell has the potential to significantly position ventures by:
Advancing critical research and innovation in Womens Health

Advancing critical research and innovation in Womens Health

with the UK's largest and only dedicated institution for Womens Health in collaboration Maroon Venture Fund, US / UK healthcare operators, and AstraWell Partners
Leveraging AstraWell resources to deliver tangible value creation

Leveraging AstraWell resources to deliver tangible value creation

.
Position ventures for commercial scaling in the  USA and UK

Position ventures for commercial scaling in the USA and UK

through AstraWell's local operations and partnerships
Accessing catalytic investment capital

Accessing catalytic investment capital

providers and optimal capital solutions for early stage ventures in global markets
Delivering game-changing impact at attractive commercial returns

Delivering game-changing impact at attractive commercial returns

.

2024 Application Deadlines

Venture Applicants

Ventures interested in applying to AstraWell Venture Studio are invited to complete questionnaire and attend the Information Session on Monday 15 July:
RSVP Here
  • Summer Cohort starts 25 July
  • Fall Cohort starts 16 Sept

Partner Opportunties

If you are not a venture, but interested in collaborating with AstraWell Venture Studio as a Strategic Partner or Investor Partner, please RSVP for Partner Webinar on Monday 15 July:
RSVP Here

Venture Eligibility Criteria

  • UK or US-domiciled
  • Pre-Seed or Seed venture growth stage
  • Patient-centric innovation
  • Strong commercial potential
  • Experienced venture team
  • Applicable Womens Health area

Womens Health Areas

  • Reproductive or Gynaecological Health ~ including cancer (breast, cervical, ovarian)
  • Chronic Population Health Conditions that disproportionately impacts women such as:
    - diabetes or other autoimmune disease
    - blood or cardiovascular conditions (incl. heart disease)
    - inflammation
    - food and environmental allergies
    - neurological, brain and mental health
  • Diversification of Clinical Trials advancing science in Womens Health
  • Healthy Ageing & Longevity
  • Blue Economy or Built Environment climate impact on Womens Health ~ Please also see Womens Catalytic Climate Fellowship for additional opportunities as a potential venture or as potential strategic partner  

About Wellbeing of Women

About Wellbeing of Women
Wellbeing of Women is the UK’s only charity dedicated to the reproductive and gynaecological health of women, girls and babies. From period problems and starting a family, to menopause and gynaecological cancers, we are here for women’s gynaecological and reproductive health. Each year, millions of women benefit from our research, our campaigns and our health information. For 60 years we’ve invested more than £68 million in research to transform women’s health and wellbeing and have funded 605 projects to date.